On November 21, 2024, Edward Ludwig, a Director at Boston Scientific Corp (BSX, Financial), sold 4,877 shares of the company, as reported in the SEC Filing. Following this transaction, the insider now owns 39,398 shares of the company.
Boston Scientific Corp (BSX) is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties. The company provides solutions that help improve the health of patients around the world.
Over the past year, Edward Ludwig has sold a total of 21,695 shares and has not purchased any shares. The insider transaction history for Boston Scientific Corp indicates that there have been no insider buys in total over the past year, while there have been 37 insider sells during the same period.
On the day of the recent sale, shares of Boston Scientific Corp were trading at $91.63 each, giving the stock a market cap of $132,644.474 million. The company's price-earnings ratio stands at 74.38, which is higher than the industry median of 28.98 and also higher than the company’s historical median price-earnings ratio.
With a trading price of $91.63 and a GF Value of $61.60, Boston Scientific Corp has a price-to-GF-Value ratio of 1.49, indicating that the stock is significantly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
